



Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data

Carl Heneghan, Alison Ward, Rafael Perera, and The Self-Monitoring Trialist Collaboration

Summary

Lancet 2012; 379: 322–34

Published Online

December 1, 2011

DOI:10.1016/S0140-

6736(11)61294-4

See [Comment](#) page 292

Oxford University, Department of Primary Care Health Sciences, Oxford, UK (C Heneghan DPhil, A Ward PhD, R Perera DPhil)

Correspondence to:

Dr Carl Heneghan, Oxford University, Department of Primary Care Health Sciences, 23–38 Hythe Bridge St, Oxford, OX1 2ET, UK
carl.heneghan@phc.ox.ac.uk

Background Uptake of self-testing and self-management of oral coagulation has remained inconsistent, despite good evidence of their effectiveness. To clarify the value of self-monitoring of oral anticoagulation, we did a meta-analysis of individual patient data addressing several important gaps in the evidence, including an estimate of the effect on time to death, first major haemorrhage, and thromboembolism.

Methods We searched Ovid versions of Embase (1980–2009) and Medline (1966–2009), limiting searches to randomised trials with a maximally sensitive strategy. We approached all authors of included trials and requested individual patient data: primary outcomes were time to death, first major haemorrhage, and first thromboembolic event. We did prespecified subgroup analyses according to age, type of control-group care (anticoagulation-clinic care vs primary care), self-testing alone versus self-management, and sex. We analysed patients with mechanical heart valves or atrial fibrillation separately. We used a random-effect model method to calculate pooled hazard ratios and did tests for interaction and heterogeneity, and calculated a time-specific number needed to treat.

Findings Of 1357 abstracts, we included 11 trials with data for 6417 participants and 12 800 person-years of follow-up. We reported a significant reduction in thromboembolic events in the self-monitoring group (hazard ratio 0·51; 95% CI 0·31–0·85) but not for major haemorrhagic events (0·88, 0·74–1·06) or death (0·82, 0·62–1·09). Participants younger than 55 years showed a striking reduction in thrombotic events (hazard ratio 0·33, 95% CI 0·17–0·66), as did participants with mechanical heart valve (0·52, 0·35–0·77). Analysis of major outcomes in the very elderly (age ≥85 years, n=99) showed no significant adverse effects of the intervention for all outcomes.

Interpretation Our analysis showed that self-monitoring and self-management of oral coagulation is a safe option for suitable patients of all ages. Patients should also be offered the option to self-manage their disease with suitable health-care support as back-up.

Funding UK National Institute for Health Research (NIHR) Technology Assessment Programme, UK NIHR National School for Primary Care Research.

Introduction

Oral anticoagulation with vitamin K antagonists substantially reduces the incidence of thromboembolic events.^{1–4} Although the number of patients receiving oral anticoagulants has consistently increased, uptake is limited by requirements to maintain the international normalised ratio (INR) within a narrow target range, which includes frequent testing and appropriate dose adjustments. Benefits shown in clinical trials might not translate into routine practice: namely the risk of major bleeding could be high in specific populations of patients, especially in the elderly.²

Introduction of reliable and analytically accurate point-of-care devices allows self-testing by the patient in the home setting.^{1,2} Patients can have their test result managed by their health-care provider (self-testing) or they can interpret their INR result, and adjust their own dose of anticoagulant accordingly (self-management).

Previous systematic reviews^{4–6} showed that self-monitoring is a safe intervention, which gives rise to significant reduction in thromboembolic events, while reducing the risk of death. Additionally, patients spend more time in the therapeutic range of INR than they

would without self-monitoring. However, previous conclusions were limited by methodological problems and inadequate reporting of important outcome data over time.^{4–6} Also important subgroup analyses, stratified by age and indication for anticoagulation therapy, have not been possible.

Uptake of self-testing and self-management has remained inconsistent in and between countries, despite good evidence of their effectiveness and guidelines encouraging patients to discuss this option with clinical staff.^{17,8} To clarify further the value of self-monitoring of oral anticoagulation we did a meta-analysis of individual patient data, which updated our previous systematic reviews and enabled more detailed analysis than previously. Specifically, we aimed to address several important gaps in the evidence, including obtaining an estimate of the effect of self-monitoring on time to death, first major haemorrhage, and first thromboembolic event. We also aimed to investigate effects in important subgroups such as the elderly and those with specific disease indications for anticoagulation such as atrial fibrillation or mechanical heart valve.

Methods

Search strategy and study selection

The protocol methods have been previously published.⁹ We used the same search strategy as for previous reviews.⁴⁻⁶ We searched Ovid versions of Embase (1980–2009) and Medline (1966–2009), limiting searches to randomised trials with a maximally sensitive strategy.¹⁰ A list of search terms is shown in webappendix pp 1–3. We modified these searches for the Cochrane Central Register of Controlled Trials, the Cochrane Library, issue 2, 2009, and Cinahl (1982–2009). We also searched for trials that are still underway or unpublished (eg, UK National Research Register and Trials Central), and hand-searched reference lists of retrieved papers.

Trial eligibility and quality assessment

We included randomised trials that compared the effects of self-monitoring (self-testing) or self-management (self-testing and self-dosage) of anticoagulation with control and dosage by personal physician, anticoagulation management clinics, or managed services, or reported the clinical outcomes of thromboembolic events and major bleeding episodes. We included studies of adults on anticoagulant therapy irrespective of the indication for treatment, with no language restrictions.

As in our previous systematic review,⁵ we assessed the quality of studies by the presence of randomisation, allocation concealment, masked outcome assessments, intention-to-treat analysis, and attrition rates. Two reviewers (CH and AW) independently assessed the articles for inclusion, and disagreements were resolved by discussion.

Data extraction

We approached all authors whose trials met the inclusion criteria and requested the following data for individual patients: date of randomisation, age, indication for treatment, type of care, demographic and psychosocial characteristics at randomisation including quality-of-life measures, treatment allocation, time to death, time to first major haemorrhage, time to first thromboembolic event, and INR measurements.

Data validation

We kept original data on a secure server with a backup copy according to a prespecified data-security-agreement policy. Two researchers (CB and AF) cross-checked trial details, summary measures, and major outcomes were cross-checked with prespecified outcome definitions against published articles. Any inconsistencies were discussed with the original trialist and corrections were made when appropriate. Requirements for authorship were those of the International Committee of Medical Journal Editors and a representative of each trial was invited to an investigators' meeting before publication to discuss analysis and results.

Statistical analysis

Primary outcomes were time to death, first major haemorrhage, and first thromboembolic events. Major haemorrhages included: 1) bleeding that was fatal, 2) symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; and 3) bleeding causing a fall in haemoglobin concentrations of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two units of packed red-blood cells. Thromboembolic events were stroke, arterial embolism, symptomatic deep-vein thrombosis, or pulmonary embolism.¹¹

One secondary outcome was time in therapeutic range. For individual data, time-to-event outcomes were summarised as log (hazard ratio), and time in range as mean (SD). We used the survival-curve and hazard-ratio programme SCHARP (version 4) for meta-analysis of individual patient data. SCHARP is an SAS application for meta-analysis of individual patient data with a point-and-click interface that produces publication-quality graphs and appropriate summary statistics for time-to-event data.¹²

We used SPSS (version 17) for analysis of baseline characteristics. We did prespecified subgroup analyses for the primary outcomes with the following age bands (<55, 55–64, 65–74, and ≥75 years), the type of control-group care, type of self-monitoring, and sex. We also analysed patients who had mechanical heart valves, atrial fibrillation, and other indications separately, stratifying them by age (<65 years and ≥65 years).

Because the components of the interventions differ somewhat (eg, in terms of their training and education) and in assuming a different underlying effect for each trial intervention, a random effects model was used to calculate pooled hazard ratios. Random effects generally lead to wider CIs than the fixed effects; however, when no heterogeneity is present the results of the fixed and random effects are equivalent. Time-to-event outcomes were analysed with hazard ratios, which take into account the number and timing of events, and the time until last follow-up for each patient not experiencing an event. We used a two-step process for meta-analysis: a hazard ratio was estimated for each trial and then hazard ratios were pooled in a meta-analysis. The log-rank observed-minus-expected statistic and its variance were calculated for each trial.¹³ We examined heterogeneity with the I^2 statistics.^{14,15} We also did tests for interaction between subgroups of patients, partitioning the total heterogeneity across all trials into within-group and between-group heterogeneity (the test for interaction). We calculated a time-specific number needed to treat at various timepoints with the method outlined by Altman and Andersen,¹⁶

$$\text{Number needed to treat} = \frac{1}{(\text{Sc}[t]^h - \text{Sc}[t])}$$

See Online for webappendix

where at a specified timepoint (t), the survival probability in the control group is $Sc(t)$, then the survival probability in the active group is $Sc(t)^h$, where h is the hazard ratio comparing the treatment groups. The number needed

to treat represents the number of patients treated in the intervention group for one less primary outcome event over the time stipulated. For subgroups, we calculated the average effect over 5 years based on the control event rate. All analyses were on an intention to treat basis. We deviated from our original protocol in that we did not present data on psychological factors, which we hope to report elsewhere.

Sufficient data from eight trials¹⁷⁻²⁴ were available for us to calculate the mean time in therapeutic range at timepoints of 7 days, 30 days, 90 days, 6 months, and 1 year by the method of linear interpolation set out by Rosendaal and colleagues.²⁵ We assessed publication bias by constructing a funnel plot of precision (SE of the log hazard ratio) against hazard ratio for the endpoints of major haemorrhage and thromboembolic events,⁶ and did Begg's and Egger's tests.¹⁵

Role of the funding source

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Of 1357 abstracts, we identified 21 trials (20 published, one unpublished) that met the eligibility criteria (figure 1). We were unable to obtain adequate data from




Figure 1: Flow chart of studies

	Country	Dates of recruitment	Year of publication of primary results	Study duration (months)	Age range, years (mean)	Total number of patients	Female	Atrial fibrillation	Mechanical valve	Other	Self management	Type of control group care
Beyth et al ^{36*}	USA	1992-95	2000	6	65-94 (74.7)	325 (5%)	184 (57%)	54 (17%)	36 (11%)	235 (72%)	No	Primary Care
Cromheecke et al ^{37†}	Holland	1998	2000	3	22-71 (42.3)	49 (1%)	21 (43%)	11 (22%)	23 (47%)	15 (31%)	Yes	Anticoagulation clinic
Koertke et al ^{38†}	Germany	1994-97	2001	24	17-77 (59.7)	930 (14%)	293 (32%)	..	930 (100%)	..	Yes	Primary care
Sunderji et al ^{37‡}	Canada	1998-2002	2004	20	20-85 (60.0)	139 (2%)	41 (29%)	47 (34%)	82 (59%)	10 (7%)	Yes	Primary care
Menéndez-Jándula et al ^{39†}	Spain	2001-02	2005	12	19-90 (63.5)	737 (11%)	347 (47%)	296 (40%)	285 (39%)	154 (21%)§	Yes	Anticoagulation clinic
Völler et al ^{38†}	Germany	1999-2001	2005	19¶	36-85 (64.4)	202 (3%)	53 (26%)	202 (100%)	Yes	Primary care
Fitzmaurice et al ^{20†}	UK	2001-02	2005	12	18-87 (65.1)	617 (10%)	217 (35%)	343 (56%)	97 (16%)	177 (29%)	Yes	Both
Christensen et al ^{21†}	Denmark	2002-03	2006	6	21-78 (50.7)	100 (2%)	33 (33%)	24 (24%)	35 (35%)	41 (41%)	Yes	Both
Siebenhofer et al ^{23†}	Austria	2002-05	2007	36	60-89 (68.8)	195 (3%)	81 (42%)	89 (46%)	32 (16%)	74 (38%)	Yes	Both
Matchar et al ^{22‡}	USA	2003-06	2010	36	23-90 (67.0)	2922 (46%)	51 (2%)	2236 (77%)	684 (23%)	2 (<1%)	No	Anticoagulation clinic
Kaatz et al ^{24†}	USA	1998-99	2001	12	30-87 (64.1)	201 (3%)	84 (42%)	86 (43%)	39 (19%)	76 (38%)	No	Anticoagulation clinic
Totals	..	1992-2006	2000-10	..	17-94 (65.0)	6417	1405 (22%)	3388 (53%)	2243 (35.0%)	784 (12%)

Data are range (mean) or number (%). *Coumatrack monitor. †CoaguChek system. ‡Pro time microcoagulation system. §Two patients were unclassified for indication. ¶Study stopped early. ||2236 with no mechanical heart valve, 2422 had atrial fibrillation, mechanical heart valve, or both.

Table 1: Characteristics of studies

ten trials.^{26–35} These trials were small, ranging from 50–320 participants (total 1181 participants). Of 21 original trials, including 7598 participants, we present results for 6417 (84%) participants.

Table 1 shows 11 included trials: three in the USA,^{22,24,36} two in Germany,^{18,38} and one each from Austria and Germany,²³ Canada,³⁷ Denmark,²¹ Netherlands,¹⁷ Spain¹⁹ and the UK.²⁰ Participant recruitment into the trials occurred from 1992 to 2006, and trials were published between 2000 and 2010. The Coaguchek (Roche Diagnostics, Basel, Switzerland), Pro time micro-coagulation (ITC Nexus Dx, Edison, NJ USA), and the Coumatrak monitor (Du Pont Pharmaceuticals, Wilmington, DE, USA) systems were used (table 1). For all trials, we verified clear methods for randomisation, allocation concealment, and intention-to-treat analyses. For publication bias, we saw no funnel-plot asymmetry and no bias with Begg's test: $p=0.35$ for thromboembolic events and $p=1.00$ for major haemorrhage; corresponding results of Egger's test were $p=0.05$ for thromboembolic events and $p=0.92$ for major haemorrhage. 3266 (51%) participants were randomly allocated to self-monitoring and 3151 to conventional care. Participants in the intervention group were on average 1.7 years (64.2 [SD 11.7] years vs 65.9 [SD 10.5] years; $p<0.0001$) younger than those in the control groups. A wide range of ages was included: from 17 to 94 years of age, with 99 participants aged 85 years or older. 12 800 person years of follow-up were obtained (mean 1.99 years [SD 1.22]), with a maximum follow-up of 1888 days (5.17 years).

Over a third of participants had a mechanical heart valve insertion; one trial¹⁸ included only participants with this indication. Over half of participants had atrial fibrillation; one trial³⁸ included only participants with this indication. For other disorders, over 10% of participants from nine trials^{17,19–24,36,37} were included. In eight trials,^{17–21,23,37,38} just under half (46%) of those in the intervention group used self-management and in three trials,^{22,24,36} just over half (54%) used self-testing only with dose adjustments undertaken by their regular clinician (table 1).

In four trials^{18,36–38} including a quarter of participants, primary care was used as the control and in another four trials^{17,19,22,24} including more than half (61%) of participants, specialist anticoagulation clinics were used (table 1). In the three remaining trials,^{20,21,23} the control included either primary care or specialist clinics (table 1).

A significant reduction in thromboembolic events was seen in the self-monitoring group (hazard ratio 0.51, 95% CI 0.31–0.85; $p=0.010$; $I^2=52.6\%$; figure 2). At 1 year, the number needed to treat to prevent one thromboembolic event was 78 (95% CI 55–253), and by 5 years it was 27 (19–87; table 2). Individual study hazard ratios are shown in webappendix p 4. No significant reduction in major haemorrhagic events (hazard ratio 0.88, 95% CI, 0.74–1.06; $p=0.18$, $I^2=0$) or in deaths




Figure 2: Hazard ratios for major outcomes

Hazard ratios for thrombotic events (152 events in the control group, 114 in the self-monitoring group; A), haemorrhagic events (244 in the control group, 230 in the self-monitoring group; B), and death (274 in the control group, 247 in the self-monitoring group; C).

(0.82, 0.62–1.09; $p=0.18$; $I^2=37.0$) were apparent with self-monitoring (figure 2).

In prespecified subgroups the rate of thromboembolic events in men was significantly reduced in the self-monitoring group (figure 3; $p=0.010$; $I^2=61.3$) whereas in women it was not (figure 3; $p=0.46$; $I^2=26.6$). However, the ratio of male to female participants was four to one (5012 men vs 1405 women) and the interaction test showed that these two subgroups did not differ significantly ($\chi^2 0.01$; $p=0.94$). Participants younger than 55 years of age who self-monitored had a striking reduction in thromboembolic events (figure 3; $p=0.002$; $I^2=0$), whereas in other age groups non-significant effects were shown. In participants younger than 55 years, this

	Number needed to treat (95% CI)	Number of patients still at risk
All participants (N=6417)		
Thrombosis		
Year 1	78 (55 to 253)	4369
Year 2	47 (33 to 154)	2513
Year 3	36 (26 to 119)	1617
Year 4	32 (23 to 104)	592
Year 5	27 (19 to 87)	..
Major Haemorrhage		
Year 1	205 (94 to ∞)	4598
Year 2	123 (59 to ∞)	2462
Year 3	96 (44 to ∞)	1564
Year 4	74 (34 to ∞)	547
Year 5	70 (32 to ∞)	..
Death		
Year 1	137 (65 to ∞)	4468
Year 2	82 (39 to ∞)	2610
Year 3	55 (26 to ∞)	1700
Year 4	47 (22 to ∞)	630
Year 5	42 (20 to ∞)	..
Mechanical valve only (n=2243)		
Thrombosis		
Year 1	55 (41 to 116)	1721
Year 2	37 (28 to 78)	589
Year 3	33 (25 to 70)	419
Year 4	31 (23 to 65)	186
Year 5	24 (18 to 50)	0
Major haemorrhage		
Year 1	127 (66 to ∞)	1699
Year 2	65 (34 to ∞)	565
Year 3	43 (22 to ∞)	386
Year 4	31 (16 to ∞)	160
Year 5	29 (15 to ∞)	..
Death		
Year 1	156 (67 to ∞)	1763
Year 2	65 (34 to ∞)	618
Year 3	43 (23 to ∞)	442
Year 4	31 (16 to ∞)	202
Year 5	29 (15 to ∞)	..
Atrial fibrillation only (n=3388)		
Thrombosis		
Year 1	185 (85 to ∞)	2386
Year 2	91 (42 to ∞)	1860
Year 3	65 (30 to ∞)	1163
Year 4	54 (25 to ∞)	393
Year 5	49 (23 to ∞)	..
Major haemorrhage		
Year 1	675 (79 to ∞)*	2344
Year 2	453 (53 to ∞)*	1824
Year 3	342 (40 to ∞)*	1134
Year 4	268 (32 to ∞)*	373
Year 5	255 (30 to ∞)*	..

(Continues in next column)

	Number needed to treat (95% CI)	Number of patients still at risk
(Continued from previous column)		
Death		
Year 1	101 (50 to ∞)	2428
Year 2	56 (28 to ∞)	1921
Year 3	37 (18 to ∞)	1216
Year 4	30 (15 to ∞)	413
Year 5	26 (13 to ∞)	..
The number needed to treat is estimated as:		
$\text{Number needed to treat} = \frac{1}{(\text{Sc}[t]^h - \text{Sc}[t])}$		
*Number needed to harm.		
Table 2: Number needed to treat at various timepoints for all self-monitoring participants with a mechanical valve and atrial fibrillation compared with standard care		

result corresponded to a number needed to treat of 21 (95% CI 17–42) to prevent one thromboembolic event at 1 year. Non-significant improvement in major outcomes was seen in the self-monitoring group with younger age (χ^2 7.75; $p=0.052$).

In terms of indication, participants with a mechanical heart valve who self-monitored had significant reductions in thromboembolic events (figure 3; $p=0.001$; $I^2=0$). At 1 year the number needed to treat to prevent one event was 55 (95% CI 41–116) and by 5 years it was 24 (18–50). Effects for both atrial fibrillation (figure 3; $p=0.35$; $I^2=40.9$) and other indications (figure 3; $p=0.12$; $I^2=0$) were not significant. An interaction test (χ^2 6.88, $p=0.032$) between indications was significant. Participants who self-managed oral anticoagulation also had significantly fewer thromboembolic events (figure 4; $p<0.001$; $I^2=0$), whereas participants self-testing alone did not (figure 4; $p=0.51$; $I^2=50.3$). The interaction test between self-testing and self-management for this difference was significant (χ^2 9.81, $p=0.002$). For participants self-managing, the number needed to treat to prevent one thromboembolic event was 39 (95% CI 31–65). For major haemorrhage and death, we detected no significant effects or interactions by age, sex, indication, or type of monitoring (figure 3).

Analysis of major outcomes in the very elderly (≥ 85 years, $n=99$) showed no significant adverse effects of self-monitoring for all outcomes, and a reduction in mortality was seen (hazard ratio 0.44, 95% CI 0.20–0.98; $p=0.044$; $I^2=0$); however, the number of participants in this analysis was small ($n=75$).

We postulated that type of control care in our pre-specified subgroups might affect the overall effectiveness of self-monitoring. Yet, little difference was seen in terms of anticoagulation clinic care versus primary care for thromboembolic events (figure 3; χ^2 2.18, $p=0.34$); major




Figure 3: Major outcomes by sex, age, indication, type of monitoring and control group care
 Thrombosis (A), major haemorrhage (B), and death (C). O-E=observed minus expected.




Figure 4: Comparison by type of monitoring (self-monitoring compared with self-testing only) Thrombosis (A), major haemorrhage (B), and death (C).




Figure 5: Major outcomes in mechanical valve and atrial fibrillation by age and sex

Patients with mechanical valve by sex and age (<65 years and ≥65 years; A) and patients with atrial fibrillation by sex and age (<65 years and ≥65 years; B). O-E=observed minus expected.

haemorrhage (χ^2 1.01, $p=0.60$), and death outcomes (χ^2 3.25, $p=0.20$).

A significant reduction in thromboembolic events was seen in men with a mechanical heart valve who were self-monitoring (figure 5; $p=0.002$, $I^2=13.8$), which was not significant in women (figure 5; $p=0.99$; $I^2=5.8$). However, the number of women was small ($n=447$ for thrombosis) and this interaction was not significant (χ^2 2.04, $p=0.15$). Men with a mechanical valve who were

self-monitoring also had a significant reduction in major haemorrhagic events (figure 5; $p=0.049$; $I^2=0$), whereas women did not (figure 5; $p=0.69$; $I^2=0$). However, the interaction test was not significant (χ^2 1.31, $p=0.25$).

Participants younger than 65 years and those 65 years or older with a mechanical heart valve who were self-monitoring oral anticoagulation showed similar significant reductions with roughly a halving of thrombotic events (figure 5). We saw no significant

	Country	7 days		30 days		90 days		6 months		1 year	
		Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control
Cromheecke et al ¹⁷	Holland	57.8 (14.5)	47.8 (18.6)
Körtke et al ¹⁸	Germany	49.2% (42.9)	56.9% (41.3)	71.2% (28.7)	55.7% (35.5)	78.2% (22.0)	59.6% (32.5)	80.9% (20.0)	60.6% (31.2)	83.0% (18.6)	61.7 (30.8)
Menéndez-Jándula et al	Spain	66.7% (37.4)	62.5% (44.7)	66.2% (26.7)	68.2% (36.2)	66.2% (18.6)	68.5% (27.2)	68.0% (16.0)	69.0% (22.3)	67.9% (14.0)	68.8 (20.0)
Fitzmaurice et al ²⁰	UK	66.6% (40.4)	53.2% (45.3)	69.7% (32.2)	63.9% (36.8)	70.7% (25.1)	63.6% (31.7)	71.0% (23.0)	63.4% (28.8)	71.7% (22.0)	63.8 (28.4)
Christensen ²¹ et al	Denmark	80.2% (24.3)	61.7% (44.1)	78.3% (24.6)	71.2% (33.7)	77.5% (20.6)	67.7% (30.9)	75.5% (18.9)	67.3% (24.5)	75.5% (18.9)	67.4 (24.2)
Siebenhofer ²³ et al	Austria	43.6% (43.5)	52.9% (44.0)	51.0% (36.6)	61.5% (35.8)	53.6% (26.2)	63.3% (29.7)	57.4% (24.5)	65.0% (26.5)	61.3% (19.9)	64.5 (21.1)
Matchar et al ²²	USA	63.3% (21.7)	52.3% (25.1)	63.5% (16.0)	53.0% (20.3)	64.1% (14.6)	55.1% (19.9)	65.1% (14.1)	57.7% (19.9)	67.2% (14.0)	61.0 (20.1)
Kaatz et al ²⁴	USA	59.7% (40.0)	61.1% (41.6)	56.6% (28.7)	66.9% (32.1)	62.9% (21.6)	70.0% (25.3)	64.7% (19.6)	71.6% (19.9)	65.9% (17.4)	70.8 (17.6)

Data are mean (SD).

Table 3: Percentage mean time in therapeutic range at 7 days to 1 year

	Time in therapeutic range			Number of tests		
	Mean difference between self-monitoring and control group (95% CI)	Heterogeneity	p value	Mean difference between self-monitoring and control group (95% CI)	Heterogeneity	p value
7 days	12.25% (8.99 to 15.51)	0	<0.001	0.25% (0.10 to 0.39)	77%	0.001
30 days	6.13% (-0.09 to 12.35)	72%	0.05	2.28% (1.59 to 2.97)	94%	<0.001
6 months	5.13% (-1.13 to 11.40)	79%	0.11	12.71% (9.33 to 16.10)	96%	<0.001
1 year	2.71% (-6.10 to 11.51)	94%	0.55	24.22% (18.40 to 30.04)	93%	<0.001

Data % or % (95% CI).

Table 4: Mean difference between self-monitoring and control group in time in therapeutic range and number of tests for participants with a mechanical valve

	Time in therapeutic range			Number of tests		
	Mean difference between self-monitoring and control group (95% CI)	Heterogeneity	p value	Mean difference between self-monitoring and control group (95% CI)	Heterogeneity	p value
7 days	10.38% (8.56 to 12.20)	0%	<0.001	0.01% (-0.25 to 0.28)	92%	0.91
30 days	3.16% (-4.07 to 10.39)	77%	0.39	1.78% (0.97 to 2.60)	97%	<0.001
6 months	4.40% (-0.86 to 9.67)	79%	0.10	12.03% (7.46 to 16.60)	99%	<0.001
1 year	5.13% (0.97 to 9.28)	57%	0.02	21.74% (13.11 to 30.37)	98%	<0.001

Data % or % (95% CI).

Table 5: Mean difference between self-monitoring and control group in time in therapeutic range and number of tests for participants with atrial fibrillation

effects or interaction in terms of major haemorrhage and death for other subgroups of participants with a mechanical valve. In participants with atrial fibrillation, we saw no significant effects across subgroups by sex or age, and no significant interactions (figure 5).

One study¹⁷ provided data only at 90 days for the mean time in therapeutic range (table 3). The time in therapeutic range improved and SDs decreased over time. By 1 year, four trials^{18,20–22} showed improvements in the intervention group, whereas the three trials,^{19,23,24} which did not show improvement, all had smaller SDs in the intervention group. In the first 7 days participants with atrial fibrillation and a mechanical heart valve who self-monitored oral

coagulation spent significantly more time in therapeutic range than did those who did not self-monitor (table 4, table 5), but over time the differences between groups reduced. Self-monitoring also led to an increase in the number of tests undertaken. At 1 year, participants with a mechanical valve or atrial fibrillation undertook more tests per year than did those receiving usual care (table 4, table 5). The substantial variation between studies was illustrated by the high heterogeneity.

Discussion

Our study used individual patient data for assessment of self-monitoring for oral anticoagulation. Overall, we

observed a significant reduction in thromboembolic events in the self-monitoring group. However, we did not find any significant effects for major haemorrhage or mortality.

Our findings accord with those of previous systematic reviews, in which patients who self-monitor or self-manage could improve the quality of their oral-anticoagulation therapy. However, despite the decrease in the number of thromboembolic events without concomitant increases in harms, we did not see the reduction in mortality shown in previous systematic reviews.^{4,6} The odds ratio in a meta-analysis by Bloomfield and colleagues³⁹ was similar to our result for reduction in thromboembolic events (odds ratio 0.58, 95% CI 0.45–0.75; $p < 0.001$). However, the result for death was similar in effect size, but the observed result differed significantly (odds ratio 0.74, 95% CI 0.63–0.87; $p < 0.001$). This effect was highly heterogeneous ($I^2 = 51\%$), which was attributed to the largest study to date.²² Reasons given for this high heterogeneity were that this large study had substantially longer follow-up and higher quality of control in the usual care group than did other similar studies. The trend for reduction in mortality favoured self-monitoring, yet our previous estimate for a reliable and conclusive treatment effect would require 5150 participants in each study group.⁶ Potentially, unavailable data from the ten studies that we were unable to access, were sufficient to remove the significance of this result.

Additionally, our previous estimate that self-monitoring was feasible for only half of patients requiring anticoagulant therapy might underestimate the true numbers. In the largest trial,²² about 80% (2922 of 3643) of trained patients were competent in the use of self-monitoring equipment. Yet, even this estimate is confounded by eligibility criteria: in several trials^{20,32} fewer than 50% of the potentially eligible patients were randomly assigned. Self-monitoring patients deemed not competent had higher numbers of practice attempts and higher cuvette wastage, and were less able to efficiently do a fingerstick procedure.⁴⁰ Factors associated with unsuccessful self-monitoring include refusal by patients, exclusion by their family practitioner, failure to pass training, old age, poor cognition, and poor manual dexterity.^{6,20,40} One trial excluded people unable to attend training,¹⁹ and in another trial²⁰ of an unselected population, young patients were more likely to successfully self-monitor oral anticoagulation.

In Germany 20% (160 000) of patients on anticoagulation undertook self-management, compared with only 1% of those in USA who did self-testing at home. Reasons for this difference include reimbursement, motivation by the patient, and willingness of the physician to support self-monitoring.²⁰ Limitations include the reluctance of individuals to participate, but also the direct costs to patients and the training required for effective monitoring.

In patients younger than 55 years of age, two-thirds reduction in thromboembolic events translated into 21 participants self-monitoring for 1 year to prevent one thromboembolic event. For patients with a mechanical heart valve, a 50% decrease in thromboembolic events meant that the number needed to undertake self-monitoring to prevent one event was 55 after 1 year and 24 over 5 years. By comparison, 63 patients are needed to prevent one heart attack with daily statin therapy over 5 years.^{41,42}

Patients who self-tested and adjusted their doses had significantly lower rates of thromboembolic events, which suggests that patients should be given the opportunity, and provided with training, to undertake self-management. However, self-management does not mean that patients are left to fend for themselves: for instance, in one trial participants had 24 h back-up available,³⁷ and good quality control measures are needed. The type of control care did not affect the overall effectiveness of self-monitoring. This finding is often contradictory to the evidence, which shows that patients from community practices have significantly worse anticoagulation control than do those from anticoagulation clinics. However, the same systematic review highlighted that patients recruited to clinical trials tended to spend more time in the therapeutic range than did those in the community.⁴³

For participants with atrial fibrillation we reported no significant effects across subgroups by sex or age, and no significant interactions. Participants with atrial fibrillation were older than those with a mechanical heart valve, and in this age group, rates of events tended to be low. In a previous trial of 973 elderly patients in the community on anticoagulation, thromboembolic events were 1.4% a year.⁴⁴

Mean time in therapeutic range tended to be better in the self-monitoring groups. Importantly, even when the time in therapeutic range showed worse control, the SDs were less, which suggests lower variation and therefore more stable control of oral anticoagulation than in the control care group.⁴⁵ Full analysis of this issue is beyond the scope of this report, but is an important issue in establishing optimum anticoagulation control.

We also reported a reduction in mortality in very elderly patients who self-monitored oral anticoagulation. This result, although potentially misleading owing to the small numbers and number of analyses, warrants further investigation. The evidence already supports the use of anticoagulation for elderly patients unless contraindications apply or patients decide the benefits are not worth the inconvenience of such treatment.⁴⁴ Our review was restricted to adults, although increasing numbers of children receive warfarin. But self-monitoring could be a safe and effective management strategy for children and clinical studies are recommended.⁴⁶

Some limitations are worth noting. First, we could have missed a study, especially because of non-publication. The results differ for publication bias because of variation

in the methods for calculating Begg's and Egger's tests. Yet, the results of both suggest a weak effect of publication bias due to effects of small studies. Second, we were unable to obtain data from ten studies, although this was a small proportion of the overall dataset, which reduced the overall sample size. However, we were able to receive data from the largest trial to date, which was recently published.²² Third, some heterogeneity in outcomes was observed. Differences occurred in the populations (ie, the monitor and the intervention populations), which all add to the inherent variability. Fourth, only a small number of participants aged over 85 years were included, and further research in this age group is needed. Finally, we do not know why fewer women than men were included and whether this is because women are reluctant to participate in self-monitoring or the overall recruitment strategies target men. One reason could be that in the largest study,²² which comprised nearly half of the data, only 1.7% of the included participants were women. Furthermore, the study was done in a Veterans Affairs population, which mainly includes men.

Adoption of self-monitoring will depend on findings from economic analyses, which in the past have produced conflicting results. In the UK, a review concluded "in general, patient self-management is unlikely to be more cost-effective than the current specialised anticoagulation clinics,"⁴⁷ whereas a Canadian study suggested: "self-management is a cost-effective strategy for patients receiving long-term oral anticoagulation therapy for atrial fibrillation or for a mechanical heart valve".⁴⁸

We believe the results of our review will lead to a systematic change in practice, in terms of the significant reduction in thromboembolic events in patients with a mechanical heart valve requiring long-term anticoagulation. Such patients should be offered the option to self-manage their disease with suitable health-care support as back-up. Additionally, several reviews and our study show that self-monitoring and self-management is a safe option for suitable patients.^{5,6,49}

Contributors

Members named in the writing committee contributed to the data collection or the systematic review and data analysis, and to the preparation of the published Article.

Collaborators

Writing committee Carl Heneghan, Alison Ward, Rafael Perera, Clare Bankhead, Alice Fuller, Richard Stevens, Kairen Bradford, Sally Tyndel (Oxford University, Oxford, UK), Pablo Alonso-Coello (Institute of Biomedical Research [IIB Sant Pau], Barcelona, Spain), Jack Ansell (Lenox Hill Hospital, New York, USA), Rebecca Beyth (University of Florida, FL, USA), Artur Bernardo (Klinik Gais AG, Gais, Switzerland), Thomas Decker Christensen (Aarhus University Hospital, Skejby, Aarhus, Denmark), M E Cromheecke (Academic Medical Centre, University of Amsterdam, Netherlands), Robert G Edson (VA Cooperative Studies Program Coordinating Center, Palo Alto, CA, USA), David Fitzmaurice (University of Birmingham, Birmingham, UK), Alain P A Gadisseur (Antwerp University Hospital, Antwerp, Belgium), Josep M Garcia-Alamino (Oxford University, Oxford, UK), Chris Gardiner (University of Oxford, Oxford, UK), J Michael Hasenkam (Aarhus University Hospital, Skejby, Aarhus, Denmark), Alan Jacobson (Loma Linda University, CA, USA), Scott Kaatz (Henry Ford Hospital, Detroit,

USA), Farhad Kamali (Newcastle University, Newcastle upon Tyne, UK), Tayyaba Irfan Khan (Newcastle University, Newcastle upon Tyne, UK), Eve Knight (Anticoagulation Europe, Kent, UK), Heinrich Körtke (Institute of Applied Telemedicine, Bad Oeynhausen, Germany), Marcel Levi (Academic Medical Centre, University of Amsterdam, The Netherlands), David Matchar (Duke-National University of Singapore Graduate Medical School, Singapore), Bárbara Menéndez-Jándula (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain), Ivo Rakovac (Institute for Biomedicine and Health Sciences, Graz, Austria), Christian Schaefer (International Self-Monitoring Association of Oral Anticoagulation Patients [ISMAAP], Geneva, Switzerland), Andrea Siebenhofer (Goethe University, Frankfurt, Germany), Juan Carlos Souto (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain), Rubina Sunderji (University of British Columbia and Vancouver General Hospital, Vancouver, Canada), Kenneth Gin (University of British Columbia and Vancouver General Hospital, Vancouver, Canada), Karen Shalansky (University of British Columbia and Vancouver General Hospital, Vancouver, Canada), Heinz Völler (Klinik am See, Rüdersdorf/Berlin, Germany), Otto Wagner (Ruhr Universität Bochum, Bad Oeynhausen, Germany), Armin Zittermann (Ruhr Universität Bochum, Bad Oeynhausen, Germany). *Analysis committee* Rafael Perera, Clare Bankhead, Richard Stevens, Carl Heneghan, Alison Ward, Alice Fuller. *Data management committee* Alison Ward, Alice Fuller, Rafael Perera, Clare Bankhead, Richard Stevens. *Original trialists* Rebecca Beyth, Thomas Decker Christensen, M E Cromheecke, Robert G Edson, David Fitzmaurice, Alain P A Gadisseur, Chris Gardiner, J Michael Hasenkam, Alan Jacobson, Scott Kaatz, Farhad Kamali, Tayyaba Irfan Khan, Heinrich Körtke, Marcel Levi, David Matchar, Bárbara Menéndez-Jándula, Ivo Rakovac, Andrea Siebenhofer, Juan Carlos Souto, Rubina Sunderji, Kenneth Gin, Karen Shalansky, Heinz Völler, Otto Wagner, Armin Zittermann.

Conflicts of interest

Department of Primary Health Care, Oxford University (UK) received funding from the National Institute for Health Research Technology Assessment Programme (NIHR HTA; UK) and NIHR National School for Primary Care Research (UK); Iberoamerican Cochrane Centre received funding from Instituto de Salud Carlos III; Jack Ansell received funding from Alere ITC; Rebecca Beyth received funding from the 5th International Patient/Physician Conference on Oral Anticoagulant Therapy and the NIHR, University of Florida, Department of Veterans Affairs, and US National Institutes of Health; Robert Edson received funding from VA Cooperative Studies Program; Alain P A Gadisseur received funding from Roche Diagnostics, Bayer Healthcare and Boehringer Ingelheim; Department of Haematology, Antwerp University Hospital (Germany) received funding from Bayer Healthcare; University College London Hospital (UK) received funding from Roche Diagnostics; J Michael Hasenkam received funding from Roche Diagnostics, Johnson & Johnson, Edwards Lifesciences, and Nycomed; Department of Cardiothoracic Surgery, Aarhus University Hospital (Denmark) received funding from National Board of Health; Alan Jacobson received funding from Anticoagulation Forum, Loma Linda Veterans Association for Research, Biosite Corporation, Boehringer Ingelheim, Daiichi Sankyo, Farallon Medical, Hemosene, Inverness Medical, Pfizer Medical, Quality Assured Services, Roche Diagnostics, Sanofi-Aventis, Tapestry Medical, GlaxoSmithKline, and VA Cooperative Studies Program and was the co-chair of the THINRS study; Department of Internal Medicine, Loma Linda University (USA) received funding from Loma Linda Veterans Association for Research, Biosite Corporation, Boehringer Ingelheim, Farallon Medical, Hemosene, Inverness Medical, and Sanofi-Aventis; Scott Kaatz received funding from Biosite and Vox media; Department of Internal Medicine, Henry Ford Hospital (USA) received funding from Roche Diagnostics; Institute of Cellular Medicine, University of Newcastle (UK) received funding from Heart Research UK; Wolfson Unit of Clinical Pharmacology, School of Clinical and Laboratory Sciences, University of Newcastle (UK) received funding from the BUPA Foundation and Coaguchek; Anticoagulation Europe received funding from Roche Diagnostics; David Matchar received funding from Boehringer Ingelheim, Roche, and VA Cooperative Studies Program and was the Co-Chair of the THINRS study; Juan Carlos Souto is the Scientific Director of Monitor Medical.

References

- 1 Fitzmaurice DA, Gardiner C, Kitchen S, Mackie I, Murray ET, Machin SJ. An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation. *Br J Haematol* 2005; **131**: 156–165.
- 2 Szucs TD, Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. *J Thromb Haemost* 2006; **4**: 1180–85.
- 3 Poller L, Keown M, Chauhan N, et al. European concerted action on anticoagulation. Quality assessment of the CoaguChek Mini and TAS PT-NC point-of-care whole-blood prothrombin time monitors. *Clin Chem* 2004; **50**: 537–44.
- 4 Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. *Int J Cardiol* 2007; **118**: 54–61.
- 5 Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. *Lancet* 2006; **367**: 404–11.
- 6 Garcia-Alamino JM, Ward AM, Alonso-Coello P, et al. Self-monitoring and self-management of oral anticoagulation. *Cochrane Database Syst Rev* 2010; **4**: CD003839.
- 7 Ansell J, Jacobson A, Levy J, Voller H, Hasenkam JM. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. *Int J Cardiol* 2005; **99**: 37–45.
- 8 Lip GY, Rudolf M, Kakar P. Management of atrial fibrillation: the NICE guidelines. *Int J Clin Pract* 2007; **61**: 9–11.
- 9 Perera R, Heneghan C, Fitzmaurice D. Individual patient meta-analysis of self-monitoring of an oral anticoagulation protocol. *J Heart Valve Dis* 2008; **17**: 233–38.
- 10 Dickersin K, Manheimer E, Wieland S, Robinson KA, Lefebvre C, McDonald S. Development of the Cochrane Collaboration's CENTRAL Register of controlled clinical trials. *Eval Health Prof* 2002; **25**: 38–64.
- 11 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost* 2005; **3**: 692–94.
- 12 Tinazzi A, Tierney J, Stewart L, Parmar M, Torri V. Survival curve and hazard ratio program (SCHARP) for meta-analysis of individual patient data. *Syst Rev Evid Action Int Cochrane Colloq 6th 1998 Baltim Md* 1998; **6**: 65.
- 13 Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007; **8**: 16.
- 14 DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177–88.
- 15 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557–60.
- 16 Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. *BMJ* 1999; **319**: 1492–95.
- 17 Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. *Lancet* 2000; **356**: 97–102.
- 18 Körtke H, Minami K, Breyman T, et al. INR self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial). *Z Kardiol* 2001; **90** (suppl 6): 118–24.
- 19 Menendez-Jandula B, Souto JC, Oliver A, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. *Ann Intern Med* 2005; **142**: 1–10.
- 20 Fitzmaurice DA, Murray ET, McCahon D, et al. Self management of oral anticoagulation: randomised trial. *BMJ* 2005; **331**: 1057.
- 21 Christensen TD, Maegaard M, Sorensen HT, Hjortdal VE, Hasenkam JM. Self-management versus conventional management of oral anticoagulant therapy: a randomized, controlled trial. *Eur J Intern Med* 2006; **17**: 260–66.
- 22 Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. *N Engl J Med* 2010; **363**: 1608–20.
- 23 Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial. *Thromb Haemost* 2008; **100**: 1089–98.
- 24 Kaatz S, Elston-Lafata J, Gooldy S. Anticoagulation therapy home and office monitoring evaluation study. *J Thromb Thrombolysis* 2001; **12**: 111.
- 25 Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. *Thromb Haemost* 1993; **69**: 236–39.
- 26 White RH, McCurdy SA, von Marensdorff H, Woodruff DE Jr, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. *Ann Intern Med* 1989; **111**: 730–37.
- 27 Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. *J Thromb Thrombolysis* 1998; **5** (suppl 1): 19–24.
- 28 Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working group for the study of patient self-management of oral anticoagulation. *JAMA* 1999; **281**: 145–50.
- 29 Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. *Br J Haematol* 2004; **126**: 557–64.
- 30 Fitzmaurice DA, Murray ET, Gee KM, Allan TF, Hobbs FD. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. *J Clin Pathol* 2002; **55**: 845–49.
- 31 Sidhu P, O'Kane HO. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. *Ann Thorac Surg* 2001; **72**: 1523–27.
- 32 Gadiisseur AP, Breukink-Engbers WG, van der Meer FJ, van den Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. *Arch Intern Med* 2003; **163**: 2639–46.
- 33 Gardiner C, Williams K, Longair I, Mackie IJ, Machin SJ, Cohen H. A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing. *Br J Haematol* 2006; **132**: 598–603.
- 34 Dauphin C, Legault B, Jaffeux P, et al. Comparison of INR stability between self-monitoring and standard laboratory method: preliminary results of a prospective study in 67 mechanical heart valve patients. *Arch Cardiovasc Dis* 2008; **101**: 753–61.
- 35 Soliman Hamad MA, van Eekelen E, van Agt T, van Straten AH. Self-management program improves anticoagulation control and quality of life: a prospective randomized study. *Eur J Cardiothorac Surg* 2009; **35**: 265–69.
- 36 Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. *Ann Intern Med* 2000; **133**: 687–95.
- 37 Sunderji R, Gin K, Shalansky K, et al. A randomized trial of patient self-managed versus physician-managed oral anticoagulation. *Can J Cardiol* 2004; **20**: 1117–23.
- 38 Völler H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study). *Z Kardiol* 2005; **94**: 182–86.
- 39 Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. *Ann Intern Med* 2011; **154**: 472–82.
- 40 Dolor RJ, Ruybalid RL, Uyeda L, et al. An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481—The Home INR Study (THINRS). *J Thromb Thrombolysis* 2010; **30**: 263–75.
- 41 Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005; **366**: 1267–78.

- 42 Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. *Arch Intern Med* 2006; **166**: 2307–13.
- 43 van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and meta-regression. *Chest* 2006; **129**: 1155–66.
- 44 Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet* 2007; **370**: 493–503.
- 45 Glasziou PP, Irwig L, Heritier S, Simes RJ. Monitoring cholesterol levels: measurement error or true change? *Ann Intern Med* 2008; **148**: 656–61.
- 46 Bauman ME, Black K, Bauman ML, et al. EMPoWarMENT: Edmonton pediatric warfarin self-management pilot study in children with primarily cardiac disease. *Thromb Res* 2010; **126**: e110–15.
- 47 Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. *Health Technol Assess* 2007; **11**: iii–66.
- 48 Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. *CMAJ* 2006; **174**: 1847–52.
- 49 Siebenhofer A, Berghold A, Sawicki PT. Systematic review of studies of self-management of oral anticoagulation. *Thromb Haemost* 2004; **91**: 225–32.